Earnings Anticipation Builds: Social media traders are gearing up for Recursion Pharmaceuticals' earnings report this week, highlighting the stock amid a packed schedule of biotech disclosures. Discussions point to potential volatility, with some eyeing short squeeze opportunities similar to past movers in the sector. The buzz reflects heightened speculation as the report approaches.
ARK Investments Steps In: Cathie Wood's ARK funds recently doubled down on RXRX shares, adding to positions in the AI-driven biotech play alongside CRISPR Therapeutics. Posters note this as a vote of confidence in the company's drug discovery platform, despite recent share sales by Nvidia. The move has sparked optimism amid broader rotations into biotech.
Technicals Signal Caution: Chart watchers observe RXRX trading around $3.50 to $3.70, with overbought RSI readings suggesting possible pullbacks despite holding key moving averages. Earlier Nvidia stake reductions weighed on sentiment, but upcoming catalysts keep bulls engaged. Overall chatter blends wariness with forward-looking hope.
Note: This discussion summary was generated from an AI condensation of post data.
Recursion Pharmaceuticals Insider Trading Activity
Recursion Pharmaceuticals insiders have traded $RXRX stock on the open market 19 times in the past 6 months. Of those trades, 0 have been purchases and 19 have been sales.
Here’s a breakdown of recent trading of $RXRX stock by insiders over the last 6 months:
- CHRISTOPHER GIBSON has made 0 purchases and 13 sales selling 820,000 shares for an estimated $3,997,000.
- BLAKE BORGESON has made 0 purchases and 3 sales selling 660,000 shares for an estimated $2,844,600.
- NAJAT KHAN (Chief R&D Commercial Officer) sold 124,403 shares for an estimated $548,592
- BEN R TAYLOR (Chief Financial Officer) has made 0 purchases and 2 sales selling 34,809 shares for an estimated $130,733.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Recursion Pharmaceuticals Revenue
Recursion Pharmaceuticals had revenues of $5.2M in Q3 2025. This is a decrease of -80.16% from the same period in the prior year.
You can track RXRX financials on Quiver Quantitative's RXRX stock page.
Recursion Pharmaceuticals Hedge Fund Activity
We have seen 184 institutional investors add shares of Recursion Pharmaceuticals stock to their portfolio, and 177 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MUBADALA INVESTMENT CO PJSC removed 12,985,927 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $53,112,441
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 12,712,693 shares (-75.7%) from their portfolio in Q4 2025, for an estimated $51,994,914
- NVIDIA CORP removed 7,706,363 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $31,519,024
- VANGUARD GROUP INC added 7,407,606 shares (+18.6%) to their portfolio in Q4 2025, for an estimated $30,297,108
- BLACKROCK, INC. added 7,127,014 shares (+22.5%) to their portfolio in Q4 2025, for an estimated $29,149,487
- STATE STREET CORP added 7,064,963 shares (+38.7%) to their portfolio in Q4 2025, for an estimated $28,895,698
- ARK INVESTMENT MANAGEMENT LLC added 3,771,357 shares (+11.2%) to their portfolio in Q4 2025, for an estimated $15,424,850
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Recursion Pharmaceuticals Analyst Ratings
Wall Street analysts have issued reports on $RXRX in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- JP Morgan issued a "Overweight" rating on 12/17/2025
- Needham issued a "Buy" rating on 09/11/2025
To track analyst ratings and price targets for Recursion Pharmaceuticals, check out Quiver Quantitative's $RXRX forecast page.
Recursion Pharmaceuticals Price Targets
Multiple analysts have issued price targets for $RXRX recently. We have seen 2 analysts offer price targets for $RXRX in the last 6 months, with a median target of $9.5.
Here are some recent targets:
- Eric Joseph from JP Morgan set a target price of $11.0 on 12/17/2025
- Gil Blum from Needham set a target price of $8.0 on 09/11/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
